This is GHDDI
The Global Health Drug Discovery Institute (GHDDI) in Beijing was jointly founded by the Bill & Melinda Gates Foundation, Tsinghua University and Beijing Municipal Government in 2016 through an innovative Public-Private Partnership (PPP). It is an independent and not-for-profit research organization, first-of-its-kind in China. Fully leveraging global resources and advantages in China, GHDDI is committed to improving global health through accelerated development of new drugs and innovative technologies to tackle diseases that disproportionately affect populations in the developing world.
Developing an effective pathway to translate seminal research discoveries into new medicines and therapies
Building a sustainable model for translational research with new mechanisms and approaches
Establishing long term impact through innovation and new policy development
Enabling and facilitating collaborations across disciplines and organizations
Impacting academic research, the healthcare industry and people around the world
GHDDI will develop a flexible resource that combines modular drug discovery infrastructure with disease-specific expertise from the academic research community. Multiple projects will be conducted in parallel within each scientific program, each targeting a distinct therapeutic approach, to create a pipeline that delivers candidates through pre-clinical development and first-in-human testing. GHDDI will maximize the probability of success by creating a diverse project portfolio within each disease program, and focuses its resources on projects that demonstrate high likelihood of progressing to the clinic. For drug candidates successfully completing first in human studies, GHDDI expects to partner with organizations with product development expertise for further clinical development.